Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312065 | 0.91 | FFAR1 (0.46) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL13312686 | 0.89 | FFAR1 (0.40) | FFAR1FFAR4DRD4ADRA1DDRD3 | |
| SCHEMBL13348393 | 0.86 | CYP2D6 (0.37) | FFAR1PTGER4PTGER2 | |
| SCHEMBL13312085 | 0.86 | FFAR1 (0.48) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL13312095 | 0.86 | FFAR1 (0.46) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL13312087 | 0.86 | PTGER4 (0.54) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL13312081 | 0.85 | PTGER4 (0.52) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL13312429 | 0.82 | FFAR1 (0.44) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL13312096 | 0.82 | FFAR1 (0.47) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL13312450 | 0.82 | FFAR1 (0.48) | FFAR1FFAR4RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | FFAR1 14/4885FFAR4 15/4885RXRA 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.